Interaction of probiotics and pathogens-benefits to human health?

Current Opinion in Biotechnology

Volumn 21, Issue 2, 2010, Pages 157-167

  Salminen, Seppo ^a   Nybom, Sonja ^b   Meriluoto, Jussi ^b   Collado, Maria Carmen ^a,c   Vesterlund, Satu ^a   El Nezami, Hani ^d  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ASSOCIATION REACTIONS; BACTERIA; CHEMICALS REMOVAL (WATER TREATMENT); DETOXIFICATION; HEALTH RISKS; HEAVY METALS; LACTIC ACID; SOLUTIONS; STRAIN; VIRUSES;

BIFIDOBACTERIA; BINDING PROCESS; DISEASE RISKS; HEALTH BENEFITS; HEALTH EFFECTS; LACTIC ACID BACTERIA; MICROBIAL SPECIES; PROBIOTIC BACTERIA;

FOOD MICROBIOLOGY;

LACTOBACILLUS CASEI EXTRACT; MYCOTOXIN; PROBIOTIC AGENT;

BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BIFIDOBACTERIUM; CLINICAL TRIAL; DIET; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG TARGETING; FOOD CONTAMINATION; FUNGAL CONTAMINATION; HOST PATHOGEN INTERACTION; HUMAN; INFECTION RISK; INFECTIOUS DIARRHEA; INTESTINE FLORA; IRRITABLE COLON; LACTIC ACID BACTERIUM; NONHUMAN; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; WATER CONTAMINATION;

EID: 77952675537     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2010.03.016     Document Type: Review

References (82)

1. Salminen S., Bouley C., Boutron-Ruault M.C., Cummings J.H., Franck A., Gibson G.R., Isolauri E., Moreau M.C., Roberfroid M., Rowland I. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998, 80(Suppl. 1):S147-S171.
2. WHO: Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria, 2001 http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
3. WHO: Guidelines for the evaluation of probiotics in foods, 2002 http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
4. Salminen S., Ouwehand A., Benno Y., Lee Y.K. Probiotics: how should they be defined?. Trends Food Sci Technol 1999, 10:107-110.
5. Ouwehand A.C., Salminen S.J. The health effects of viable and non-viable cultured milks. Int Dairy J 1998, 8:749-758.
6. Perez P.F., Doré J., Leclerc M., Levenez F., Benyacoub J., Serrant P., Segura-Roggero I., Schiffrin E.J., Donnet-Hughes A. Bacterial imprinting of the neonatal immune system: lessons from maternal cells?. Pediatrics 2007, 119:e724-e732.
7. Halttunen T., Collado M.C., El-Nezami H., Meriluoto J., Salminen S. Mixing of lactic acid bacteria strains may reduce their toxin removal efficiency from aqueous solution. Lett Appl Microbiol 2008, 46(2):160-165.
8. Nybom S.M.K., Salminen S.J., Meriluoto J.A.O. Removal of microcystin-LR by strains of metabolically active probiotic bacteria. FEMS Microbiol Lett 2007, 270:27-33.
9. El-Nezami H., Kankaanpaa P., Salminen S., Ahokas J. Ability of dairy strains of lactic acid bacteria to bind a common food carcinogen, aflatoxin B1. Food Chem Toxicol 1998, 36:321-326.
10. Haskard C.A., El-Nezami H.S., Kankaanpää P.E., Salminen S., Ahokas J.T. Surface binding of aflatoxin B(1) by lactic acid bacteria. Appl Environ Microbiol 2001, 67:3086-3091.
11. Fooks L.J., Fuller R., Gibson G.R. Prebiotics, probiotics and human gut microecology. Int Dairy J 1999, 9:53-61.
12. Servin A.L. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004, 28:405-440.
13. Timmerman H.M., Koning C.J., Mulder L., Rombouts F.M., Beynen A.C. Monostrain, multistrain and multispecies probiotics-a comparison of functionality and efficacy. Int J Food Microbiol 2004, 96:219-233.
14. Schell M., Karmirantzou M., Snel B., Vilanova D., Berger B., Pessi G., Zwahlen M.C., Desiere F., Bork P., Delley M., et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci 2002, 99:14422-14427.
15. Myllyluoma E., Veijola L., Ahlroos T., Tynkkynen S., Kankuri E., Vapaatalo H., Rautelin H., Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005, 21:1263-1272.
16. Kajander K., Hatakka K., Poussa T., Farkkila M., Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005, 22:387-394.
17. Olivares M., Diaz-Ropero M.P., Gómez N., Lara-Villoslada F., Sierra S., Maldonado J.A., Martín R., Rodríguez J.M., Xaus J. The consumption of two new probiotic strains. Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int Microbiol 2006, 9:47-52.
18. Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005, 17(5):687-696.
19. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., Nieuwenhuijs V.B., Bollen T.L., van Ramshorst B., Witteman B.J., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659. Dutch Acute Pancreatitis Study Group.
20. Schachtsiek M., Hammes W.P., Hertel C. Characterization of Lactobacillus coryniformis DSM 20001T surface protein Cpf mediating coaggregation with and aggregation among pathogens. Appl Environ Microbiol 2004, 70:7078-7085.
21. Collado M.C., Isolauri E., Salminen S. Role of probiotic strains and their combinations in Enterobacter sakazakii in vitro infection associated with powdered infant formula. FEMS Microbiol Lett 2008, 285:58-64.
22. Alander M., Satokari R., Korpela R., Saxelin M., Vilpponen-Salmela T., Mattila-Sandholm T., von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain. Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999, 65:351-354.
23. Ouwehand A.C., Isolauri E., Kirjavainen P.V., Tölkko S., Salminen S.J. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol 2000, 30:10-13.
24. Collado M.C., Meriluoto J., Salminen S. Measurement of aggregation properties between probiotics and pathogens: in vitro evaluation of different methods. J Microbiol Methods 2007, 71:71-74.
25. Kajander K., Myllyluoma E., Rajilić-Stojanović M., Kyrönpalo S., Rasmussen M., Järvenpää S., Zoetendal E.G., de Vos W.M., Vapaatalo H., Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008, 27:48-57.
26. Bibiloni R., Fedorak R.N., Tannock G.W., Madsen K.L., Gionchetti P., Campieri M., De Simone C., Sartor R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005, 100:1539-1546.
27. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 2006, 40:264-269.
28. Gionchetti P., Lammers K.M., Rizzello F., Campieri M. Probiotics and barrier function in colitis. Gut 2005, 54:898-900.
29. Gaudier E., Michel C., Segain J.P., Cherbut C., Hoebler C. The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J Nutr 2005, 135:2753-2761.
30. Kalliomäki M., Salminen S., Arvilommi H., Kero P., Koskinen P., Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001, 357:1076-1079.
31. Kukkonen K., Savilahti E., Haahtela T., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., Kuitunen M. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007, 119:192-198.
32. Collado M.C., Meriluoto J., Salminen S. Development of new probiotics by strain combinations: is it possible to improve the adhesion to intestinal mucus. J Dairy Sci 2007, 90:2710-2716.
33. Collado M.C., Meriluoto J., Salminen S. Interactions between pathogens and lactic acid bacteria: aggregation and coaggregation abilities. Eur J Food Res Technol 2008, 226:1065-1073.
34. Barker J., Stevens D., Bloomfield S.F. Spread and prevention of some common viral infections in community facilities and domestic homes. J Appl Microbiol 2001, 91:7-21.
35. Guarino A., Canani R.B., Spagnuolo M.I., Albano F., Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997, 25:516-519.
36. Shornikova A.-V., Casas I., Mykkänen H., Salo E., Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997, 16:1103-1107.
37. Shornikova A.V., Isolauri E., Burkanova L., Lukovnikova S., Vesikari T. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. Acta Paediatr 1997, 86:460-465.
38. Isolauri E., Juntunen M., Rautanen T., Sillanaukee P., Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991, 88:90-97.
39. Saavedra J.M., Bauman N.A., Oung I., Perman J.A., Yolken R.H. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994, 344:1046-1049.
40. Giovannini M., Agostoni C., Riva E., Salvini F., Ruscitto A., Zuccotti G.V., Radaelli G. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res 2007, 62:215-220.
41. Hatakka K., Savilahti E., Ponka A., Meurman J.H., Poussa T., Nase L., Saxelin M., Korpela R. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001, 322:1327.
42. Cobo Sanz J.M., Mateos J.A., Munoz Conejo A. Effect of Lactobacillus casei on the incidence of infectious conditions in children. Nutr Hosp 2006, 21:547-551.
43. de Vrese M., Winkler P., Rautenberg P., Harder T., Noah C., Laue C., Ott S., Hampe J., Schreiber S., Heller K. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3. B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr 2005, 24:481-491.
44. de Vrese M., Winkler P., Rautenberg P., Harder T., Noah C., Laue C., Ott S., Hampe J., Schreiber S., Heller K. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine 2006, 24:6670-6674.
45. Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br J Nutr 2009, 3:1-11.
46. Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy-a randomised, double-blind, placebo-controlled study. Br J Nutr 2009, 101:1722-1726.
47. Leyer G.J., Li S., Mubasher M.E., Reifer C., Ouwehand A.C. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics 2009, 124:e172-179.
48. Winkler P., de Vrese M., Laue C., Schrezenmeir J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. Int J Clin Pharmacol Ther 2005, 43:318-326.
49. Mullie C., Yazourh A., Thibault H., Odou M.F., Singer E., Kalach N., Kremp O., Romond M.B. Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr Res 2004, 56:791-795.
50. Isolauri E., Joensuu J., Suomalainen H., Luomala M., Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995, 13:310-312.
51. Salminen S.J., Gueimonde M., Isolauri E. Probiotics that modify disease risk. J Nutr 2005, 135:1294-1298.
52. Isolauri E., Sütas Y., Kankaanpää P., Arvilommi H., Salminen S. Probiotics: effects on immunity. Am J Clin Nutr 2001, 73(2 Suppl.):444S-450S.
53. Hussein H.S., Brasel J.M. Toxicity, metabolism, and impact of mycotoxins on humans and animals. Toxicology 2001, 167:101-134.
54. Turbic A., Ahokas J.T., Haskard C.A. Selective in vitro binding of dietary mutagens, individually or in combination, by lactic acid bacteria. Food Addit Contam 2002, 19:144-152.
55. El-Nezami H., Kankaanpaa P., Salminen S., Ahokas J. Physicochemical alterations enhance the ability of dairy strains of lactic acid bacteria to remove aflatoxin from contaminated media. J Food Prot 1998, 61:466-468.
56. Peltonen K., el-Nezami H., Haskard C., Ahokas J., Salminen S. Aflatoxin B1 binding by dairy strains of lactic acid bacteria and bifidobacteria. J Dairy Sci 2001, 84:2152-2156.
57. Oatley J.T., Rarick M.D., Ji G.E., Linz J.E. Binding of aflatoxin B1 to bifidobacteria in vitro. J Food Prot 2000, 63:1133-1136.
58. Pierides M., El-Nezami H., Peltonen K., Salminen S., Ahokas J. Ability of dairy strains of lactic acid bacteria to bind aflatoxin M1 in a food model. J Food Prot 2000, 63:645-650.
59. El-Nezami H., Haskard C., Salminen E., Mykkänen A., Ahokas J., Salminen S. Lactic acid bacteria and bifidobacteria can reduce dietary exposure to aflatoxins. Br J Nutr 2002, 88:S115-116.
60. El-Nezami H.S., Chrevatidis A., Auriola S., Salminen S., Mykkanen H. Removal of common Fusarium toxins in vitro by strains of Lactobacillus and Propionibacterium. Food Addit Contam 2002, 19:680-686.
61. El-Nezami H., Polychronaki N., Salminen S., Mykkanen H. Binding rather than metabolism may explain the interaction of two food-Grade Lactobacillus strains with zearalenone and its derivative (')alpha-earalenol. Appl Environ Microbiol 2002, 68:3545-3549.
62. Haskard C.A., El-Nezami H.S., Kankaanpaa P.E., Salminen S., Ahokas J.T. Surface binding of aflatoxin B(1) by lactic acid bacteria. Appl Environ Microbiol 2001, 67:3086-3091.
63. Haskard C., Binnion C., Ahokas J. Factors affecting the sequestration of aflatoxin by Lactobacillus rhamnosus strain GG. Chem Biol Interact 2000, 128:39-49.
64. El-Nezami H., Mykkanen H., Kankaanpää P., Salminen S., Ahokas J. Ability of Lactobacillus and Propionibacterium strains to remove aflatoxin B, from the chicken duodenum. J Food Prot 2000, 63:549-552.
65. El-Nezami H.S., Polychronaki N.N., Ma J., Zhu H., Ling W., Salminen E.K., Juvonen R.O., Salminen S.J., Poussa T., Mykkanen H.M. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr 2006, 83:1199-1203.
66. Mykkanen H., Zhu H., Salminen E., Juvonen R.O., Ling W., Ma J., Polychronaki N., Kemilainen H., Mykkanen O., Salminen S., El-Nezami H. Fecal and urinary excretion of aflatoxin B1 metabolites (AFQ1, AFM1 and AFB-N7-guanine) in young Chinese males. Int J Cancer 2005, 115:879-884.
67. Sivonen K., Jones G. Cyanobacterial toxins. Toxic Cyanobacteria in Water: A Guide to their Public Health Consequences, Monitoring, and Management 1999, 41-111. E&FN Spon, London. I. Chorus, J. Bartram (Eds.).
68. Honkanen R.E., Zwiller J., Moore R.E., Daily S.L., Khatra B.S., Dukelow M., Boynton A.L. Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J Biol Chem 1990, 265:19401-19404.
69. MacKintosh C., Beattie K.A., Klumpp S., Cohen P., Codd G.A. Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. FEBS Lett 1990, 264:187-192.
70. Kuiper-Goodman T., Falconer I., Fitzgerald J. Human health aspects. Toxic Cyanobacteria in Water: A Guide to their Public Health Consequences, Monitoring, and Management 1999, 113-153. E&FN Spon, London. I. Chorus, J. Bartram (Eds.).
71. Jones G.J., Orr P.T. Release and degradation of microcystin following algicide treatment of a Microcystis aeruginosa bloom in a recreational lake, as determined by HPLC and protein phosphatase inhibition assay. Water Res 1994, 28:871-876.
72. Toxic Cyanobacteria in Water, A Guide to Their Public Health Consequences, Monitoring and Management 1999, E&FN Spon, London. I. Chorus, J. Bartram (Eds.).
73. Jochimsen E.M., Carmichael W.W., An J.S., Cardo D.M., Cookson S.T., Holmes C.E.M., Antunes M.B., de Melo Filho D.A., Lyra T.M., Barreto V.S.T., et al. Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil. N Engl J Med 1998, 338:873-878.
74. Pouria S., de Andrade A., Barbosa J., Cavalcanti R.L., Barreto V.T.S., Ward C.J., Preiser W., Poon G.K., Neild G.H., Codd G.A. Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. Lancet 1998, 352:21-26.
75. Nybom S.M.K., Collado M.C., Surono I.S., Salminen S.J., Meriluoto J.A.O. Effect of glucose in removal of microcystin-LR by viable commercial probiotic strains and strains isolated from dadih fermented milk. J Agric Food Chem 2008, 56:3714-3720.
76. Nybom S.M.K., Salminen S.J., Meriluoto J.A.O. Specific strains of probiotic bacteria are efficient in removal of several different cyanobacterial toxins from solution. Toxicon 2008, 52:214-220.
77. Bourne D.G., Jones G.J., Blakeley R.L., Jones A., Negri A.P., Riddles P. Enzymatic pathway for the bacterial degradation of the cyanobacterial cyclic peptide toxin microcystin LR. Appl Environ Microbiol 1996, 62:4086-4094.
78. Park H.D., Sasaki Y., Maruyama T., Yanagisawa E., Hiraishi A., Kato K. Degradation of the cyanobacterial hepatotoxin microcystin by a new bacterium isolated from a hypertrophic lake. Environ Toxicol 2001, 16:337-343.
79. Harada K., Imanishi S., Kato H., Mizuno M., Ito E., Tsuji K. Isolation of Adda from microcystin-LR by microbial degradation. Toxicon 2004, 44:107-109.
80. Bourne D.G., Riddles P., Jones G.J., Smith W., Blakeley R.L. Characterisation of a gene cluster involved in bacterial degradation of the cyanobacterial toxin microcystin LR. Environ Toxicol 2001, 16:523-534.
81. von Ossowski I., Reunanen J., Satokari R., Vesterlund S., Kankainen M., Huhtinen H., Tynkkynen S., Salminen S., de Vos W.M., Palva A. The mucosal adhesion properties of the probiotic Lactobacillus rhamnosus GG SpaCBA and SpaFED pilin subunits. Appl Environ Microbiol 2010 Jan 29, [Epub ahead of print].
82. Kankainen M., Paulin L., Tynkkynen S., von Ossowski I., Reunanen J., Partanen P., Satokari R., Vesterlund S., Hendrickx A.P., Lebeer S., et al. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein. Proc Natl Acad Sci USA 2009, 106:17193-17198.